Hot! Delta and Omicron Mutated Strains are Available!
*Shipping time varies country by country, please quote for more detail.
Entry of Coronavirus into host cells is mediated by the trimeric transmembrane spike (S) glycoprotein (Fig. 1). S glycoprotein is surface-exposed and mediates entry into the host cells by binding to human angiotensin-converting enzyme 2 (ACE2), the SARS-CoV-2 receptor, which makes S glycoprotein the major target of neutralizing antibodies and the focus of therapeutic and vaccine design.
A model that simulates the infection of the SARS-CoV-2 is designed by replacing the envelope glycoprotein in the lentivirus vector with the S protein. Neutralizing antibodies blocking S protein (Fig. 2). and receptor binding could prevent the virus from infecting host cells. By detecting the luminescence of target cells, it is possible to screen or verify the activity of the neutralizing antibody.
GenScript ProBio provides not only assay service but also neutralization kit, meeting all your needs for both research and industry application.
Fig.1 Pseudovirus with S glycoprotein as the envelope protein
Fig.2 Neutralizing antibodies preventing the pseudovirus from entering host cells
Delivery: Neutralization assay report
QC standard: S/N ≥ 100
Turnaround time: 1-3 weeks*
Wild type:4 weeks
* Components can be purchased separately. Please contact us.
Pseudovirus neutralization assay
Live virus neutralization assay
Figure 1. Comparable IC50 values of live virus and pseudovirus neutralization assay using the same sample.
Neutralization by ACE2-Fc
Figure 2. Positive control ACE2-Fc can effectively inhibit pseudovirus entry in a dose-dependent manner
Consistent IC50 in independent tests
Figure 3. Antibody candidates were screened for their ability to inhibit pseudovirus entry.
Neutralization by immunized mice serum
Figure 4. Immunized mouse serum can effectively inhibit pseudovirus entry
Figure 5. B.1.617.2 pseudovirus (Delta variant) was efficiently blocked by ACE2-Fc chimera proteins (left panel). RBD-63 mAb failed to inhibit the B.1.617.2 pseudovirus (Delta variant) infection (right panel).
Figure 6. Blocking Omicron pseudovirus entry into ACE2 overexpressing target cells by means of ACE2-Fc chimera protein.